Studies utilizing similar NPs loaded with cisplatin and conjugated to antibodies against VEGF and its receptor type II (VEGFR2) have since demonstrated enhanced drug delivery and uptake by glioma cells in vivo [120]. The gene discussed is VEGFA; the disease is central nervous system cancer.